Why the study?
Does a 6-hour continuous infusion of doxorubicin reduce cardiotoxicity compared to a rapid 15-20 minute infusion in patients with metastatic breast or ovarian cancer?
Does a 6-hour continuous infusion of doxorubicin reduce cardiotoxicity compared to a rapid 15-20 minute infusion in patients with metastatic breast or ovarian cancer?
Administering doxorubicin as a 6-hour continuous infusion rather than a rapid bolus significantly reduces the decline in LVEF and the risk of clinical congestive heart failure.
No takes yet. Share an insight, caveat, or question.
Supports 6-hour doxorubicin infusion to reduce cardiotoxicity in metastatic breast/ovarian cancer; confirms benefit of prolonged over bolus administration.
Shapira et al. (1990) studied this question.
Synapse has enriched 4 closely related papers on similar clinical questions. Consider them for comparative context: